Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

被引：0

作者：

VIR-SINGH NEGI

SRIRAMULU ELLURU

SOPHIE SIBÉRIL

STÉPHANIE GRAFF-DUBOIS

LUC MOUTHON

MICHEL D. KAZATCHKINE

SÉBASTIEN LACROIX-DESMAZES

JAGADEESH BAYRY

SRINI V. KAVERI

机构：

[1] Université Pierre et Marie Curie (UPMC Paris-6) and Equipe 16-Immuno-pathology and Therapeutic Intervention,INSERM UMRS 872, Université René Descartes (Paris

[2] Centre de Recherche des Cordeliers,5)

[3] Université de Technologie,Department of Medicine

[4] Jawaharlal Institute of Postgraduate Medical Education and Research,Service de Médecine Interne

[5] Centre de Référence pour les vascularites et la sclérodermie systémique,INSERM UMRS 872

[6] Assistance Publique-Hôpitaux de Paris,undefined

[7] Hôpital Cochin,undefined

[8] Faculté de Médecine,undefined

[9] Université Paris-Descartes,undefined

[10] Equipe 16-Immunopathology and Therapeutic Intervention,undefined

[11] Centre de Recherche des Cordeliers,undefined

来源：

Journal of Clinical Immunology | 2007年 / 27卷

关键词：

Intravenous immunoglobulins; autoimmunity; inflammation; immune-modulation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Initially used as a replacement therapy for immunodeficiency diseases, intravenous immunoglobulin (IVIg) is now widely used for a number of autoimmune and inflammatory diseases. Considerable progress has been made in understanding the mechanisms by which IVIg exerts immunomodulatory effects in autoimmune and inflammatory disorders. The mechanisms of action of IVIg are complex, involving modulation of expression and function of Fc receptors, interference with activation of complement and the cytokine network and of idiotype network, regulation of cell growth, and effects on the activation, differentiation, and effector functions of dendritic cells, and T and B cells.

引用

页码：233 / 245

页数：12

共 831 条

[1] Kazatchkine MD(2001)Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin N Engl J Med 345 747-755
[2] Kaveri SV(2007)Drug Insight: The use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues Nat Clin Pract Neurol 3 36-44
[3] Gold R(2004)Intravenous immunoglobulin in autoimmune neuromuscular diseases JAMA 291 2367-2375
[4] Stangel M(2002)Origins and functions of B-1 cells with notes on the role of CD5 Annu Rev Immunol 20 253-300
[5] Dalakas MC(1998)Self-reactive antibodies (natural autoantibodies) in healthy individuals J Immunol Methods 216 117-137
[6] Dalakas MC(2003)Predominant autoantibody production by early human B cell precursors Science 301 1374-1377
[7] Berland R(1989)Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig J Immunol 143 4104-4109
[8] Wortis HH(1989)Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses Immunol Rev 110 135-149
[9] Lacroix-Desmazes S(1992)Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain Proc Natl Acad Sci USA 89 3325-3329
[10] Kaveri SV(1993)Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) Clin Exp Immunol 92 369-372

← 1 2 3 4 5 6 7 8 9 10 →